2-Pyrrolidone

2-Pyrrolidone

SCHEMBL1048019

Br.Br.Br.O=C1CCCN1.O=C1CCCN1.O=C1CCCN1

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of 2-Pyrrolidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 1/20 0.94
CRBN Q96SW2 5/20 0.78
FKBP5 Q13451 1/20 0.78
KDM4E B2RXH2 2/20 0.45
GAA P10253 2/20 0.45
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KMT2A Q03164 1/20 0.32
GRIA1 P42261 1/20 0.31
GRIA2 P42262 1/20 0.31
GRIA3 P42263 1/20 0.31
GRIA4 P48058 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HSP90AA1 P07900 1/20 0.31
TRIM24 O15164 1/20 0.30
TRIM33 Q9UPN9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Pyrrolidone SCHEMBL4367304 1.00
2-Pyrrolidone SCHEMBL511486 1.00
2-Pyrrolidone SCHEMBL28877688 0.97
2-Pyrrolidone SCHEMBL28933712 0.97
2-Pyrrolidone SCHEMBL9441874 0.97
2-Pyrrolidone SCHEMBL27827832 0.97
2-Pyrrolidone SCHEMBL4299593 0.97
2-Pyrrolidone SCHEMBL9304498 0.97 OR51E2 (1.00) OR51E2CRBNFKBP5KDM4EGAA
2-Pyrrolidone SCHEMBL2389 0.97
2-Pyrrolidone SCHEMBL2167448 0.97 OR51E2 (1.00) OR51E2CRBNFKBP5KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120004697-A Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material 同济大学 2025-05-16 CN claimed
US-20250195502-A1 APPLICATION OF TETRACYCLIC COMPOUND IN TREATMENT OF TUMORS SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US disclosed
CN-120004697-A Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material 同济大学 2025-05-16 CN disclosed
WO-2024114765-A9 BENZOPYRONE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 成都地奥九泓制药厂 2025-04-03 WO disclosed
EP-4491182-A1 APPLICATION OF TETRACYCLIC COMPOUND IN TREATMENT OF TUMORS Shanghai Shijiang Biotechnology Co., Ltd (CN) 2025-01-15 EP disclosed
WO-2024114765-A1 BENZOPYRONE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 成都地奥九泓制药厂 2024-06-06 WO disclosed
CN-111954685-B Process for producing 4-methyl-1-pentene polymer particles and 4-methyl-1-pentene resin 三井化学株式会社 2023-08-08 CN disclosed
CN-111954685-A 4-methyl-1-pentene polymer particles and method for producing 4-methyl-1-pentene resin 三井化学株式会社 2020-11-17 CN disclosed
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-7906522-B2 2-aminoquinazoline derivatives KYOWA HAKKO KIRIN CO., LTD (JP) 2011-03-15 US disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed
US-20090137583-A1 2-AMINOQUINAZOLINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-28 US disclosed
EP-1878727-A1 2-AMINOQUINAZOLINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-16 EP disclosed
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 OR51E2 3344/4885CRBN 2435/4885FKBP5 3139/4885
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 OR51E2 3271/4885CRBN 3374/4885FKBP5 4138/4885
US-20090137583-A1 2-AMINOQUINAZOLINE DERIVATIVES SLC7A1, SLC38A7, PRMT7 OR51E2 2236/4885CRBN 122/4885FKBP5 4052/4885
US-20250195502-A1 APPLICATION OF TETRACYCLIC COMPOUND IN TREATMENT OF TUMORS NNMT, UHRF1, TET1 OR51E2 1488/4885CRBN 3112/4885FKBP5 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.